A Phase 1 Study of MM-141 in Patients With Advanced Solid Tumors

Inclusion Criteria:

- Advanced malignant solid tumors for which no curative therapy exists that has
recurred or pgrogressed following standard therapy

- Eighteen years of age or above

- Able to understand and sign an informed consent (or have a legal representative who
is able to do so)

- Measurable disease according to RECIST v1.1

- ECOG Performance Score of 0 or 1

- Adequate bone marrow, hepatic, renal and cardiac function

- Willing to abstain from sexual intercourse or to use an effective form of
contraception during the study and for 90 days following the last dose of MM-141

Exclusion Criteria:

- Active infection or fever > 38.5°C during screening visits or on the first scheduled
day of dosing

- Symptomatic CNS disease

- Received other recent antitumor therapy

- Pregnant or breast feeding